ImmunityBio, Inc. Annual Net Cash Provided by (Used in) Financing Activities in USD from 2016 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
ImmunityBio, Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from 2016 to 2023.
  • ImmunityBio, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2024 was $10.2M, a 86.7% decline year-over-year.
  • ImmunityBio, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $558M, a 139% increase from 2022.
  • ImmunityBio, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $234M, a 53.8% decline from 2021.
  • ImmunityBio, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2021 was $505M, a 235% increase from 2020.
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $558M +$325M +139% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-19
2022 $234M -$272M -53.8% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-19
2021 $505M +$355M +235% Jan 1, 2021 Dec 31, 2021 10-K 2024-03-19
2020 $151M +$36.4M +31.8% Jan 1, 2020 Dec 31, 2020 10-K 2023-03-01
2019 $114M +$115M Jan 1, 2019 Dec 31, 2019 10-K 2022-03-01
2018 -$771K +$34.2M +97.8% Jan 1, 2018 Dec 31, 2018 10-K 2021-03-04
2017 -$35M -$19.4M -125% Jan 1, 2017 Dec 31, 2017 10-K 2020-03-25
2016 -$15.6M Jan 1, 2016 Dec 31, 2016 10-K 2019-03-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.